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Abstract 
 
A label-free nanoparticle array platform has been used to detect total peanut allergen-specific 
binding from whole serum of patients suffering from peanut allergy. The serum from 10 patients 
was screened against a four-allergen panel of cat and dog dander, dust mite and peanut allergen 
protein Ara h1. The IgE and IgG contributions to the total specific-binding protein load to Ara h1 
was identified using two secondary IgG- and IgE- specific antibodies and were found to contribute 
less than 50% of the total specific protein load. The total mass of IgE, IgE and the unresolved  
specific-binding protein, sBP, for Ara h1 provides a new serum profile for high Rast grade 
patients, 5 and 6 with the IgG/IgE ratio of 4±2 and sBP/IgE ratio of 17 ± 11, neither of which are 
protective for the small-patient cohort.  
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Introduction 
Food allergy continues to rise in the US and Europe with peanut allergy suffers producing 
the largest group of allergy-related fatalities (1-4). In the US as many as 2% of children are peanut 
allergic, often having multiple allergies, leading to a disproportionately large number of deaths (5) 
and prompting some scientists to consider an approaching peanut allergy epidemic (6). The exact 
cause of developing a peanut allergy is unknown (7) and more interestingly 80% of children with 
peanut allergy grow out of it in early adult life: the mechanism of evolving tolerance is poorly 
understood (8). 
The conventional diagnosis of peanut allergy starts with report of an episode in a clinical 
history, which may be followed by a skin prick test to measure the weal response and then a test 
for peanut-specific IgE levels in the serum. A number of peanut allergens have been identified and 
classified as Ara h 1-11 (9) although the standard ImmunoCap assay platform uses an extract 
called f13, which is likely a mixture of Ara h 1-3, in its peanut-specific IgE assay. Despite the 
extensive research into the identification of allergens, the precise epitope presentation in a 
particular detection platform may lead to significant variations in absolute IgE concentration 
measurements across platforms, although the results appear to correlate (10). The surface area of 
the ImmuoCap and the allergen presentation have been optimized to produce the largest consistent 
IgE absolute concentration determination. 
The serum IgE diagnosis of peanut allergy is not precise with conflicts between positive 
results from skin prick tests and negative serum IgE levels. In one study, only 22% of eight-year-old 
children showing either a positive result to skin-prick test or serum IgE but did not show a positive 
response to oral peanut challenge (11). Neither the skin prick test nor the serum IgE levels are an 
accurate positive predictor of peanut allergy as determined by the oral peanut challenge. Currently, 
serum concentrations of 15 kUA/L (36 g /L, Rast grade 3) specific IgE binding to peanut f13 
extract and a wheal of 8mm form the skin prick test predicts with greater than 95% accuracy true 
peanut allergy (12). However, many peanut allergy sufferers have much lower levels with varying 
degrees of sensitivities, severity and tolerance. Reduction of the f13 extract to a component 
diagnosis suggests that the Ara h2 is the most efficient with a increased positive predictive value of 
95 % as a serum test alone (13) but does not show region specificity (14). A full component 
analysis Ara h1 – 11 reveals cross-reactivity between food allergies and regional variations (15).  
In addition, to IgE allergen specificity, large serum concentrations of IgG for food allergy epitopes 
(16), specifically the IgG4 isotype, are found in the serum of patients with IgG to food, especially 
egg white, orange, wheat and rice correlating with IgE to cat, dog, mite and milk (17). Food allergy 
has been further linked to birch pollen and IgG4 (18). From these observations there would appear 
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to be a spectrum of epitopes in the food protein digestion products for which there are significant 
IgG and IgE concentrations in the serum. 
Previously, we have measured the effects of competitive binding on nanoparticle 
biophotonic surfaces between non-specific and specific binding proteins in whole serum (19, 20) 
leading to interferences in the quantitative response of the assay. This interference effect is not 
unique to label-free technologies and determining the relative contributions of non-specific and 
specific binding when screening a complex fluid such as blood is important for any assay. Most 
platforms use a label to detect only the target, a presumptive test. However, in blood there may be 
a number of proteins and antibodies that compete specifically with the target protein on the assay 
which, would be detected by label-free technologies, providing an advantage in screening whole 
blood for patient diagnosis. In part, competitive specific binding addresses the question of the 
correlation between measurements on different platforms giving different reported levels of IgE 
levels (10). Most sensor platforms measure an endpoint with the surface concentration of IgE 
detected after a long incubation time with the sensor surface. A subsequent sensing event, such as 
ELISA tagged antibody, then visualizes and quantifies the IgE concentrations. Sensor surfaces with 
different sensor areas, however, may become quickly filled with specific-binding proteins (sBP) 
preventing allergy-relevant IgE binging in some patients where sBP dominates the phenotype.  
The immuno-kinetic response on the label-free biosensor platform is surface-area limited, 
which means the two target antibodies IgG and IgE compete for the available specific binding sites 
on the sensor surface coated with the target antigen. This is analgous to the rapid covering of the 
allergenic surface in the membranes of the upper GI track by IgG  which would prevent IgE binding 
and mitigate the IgE-triggered allergic response. By contrast, the surface area of the ImmunoCap 
sensors is very large allowing all of the IgE to bind to the surface irrespective of the high IgG 
concentration resulting in a stable IgE determination and subsequent RAST classification; a serum 
positive.   
In this paper, we investigate the total specific binding proteins, sBP, from patient serum 
samples to a particular allergen; a broad measure of the patient’s allergen phenotype. We 
investigated the total protein load binding, sBP to the peanut allergen Ara h1 epitopes presented on 
a gold nanoparticle plasmon sensor surface. The components of sBP are partially resolved into IgG 
and IgE based on secondary antibody detection of the already-bound proteins. 
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Materials and Methods 
Array Reader 
The biophotonic nanoparticle array sensor technology is based on the change in scatted 
light intensity from nanoparticle-functionalised array elements and has been described in detail 
elsewhere (20, 21). Briefly, nanoparticles are printed into an 96-element array format with seed 
nanoparticles of 4 nm in diameter and are then grown 120 nm particles to optimise the scattering 
sensitivity. Each element of the array is then printed with the target proteins such as the Ara h 1 
peanut allergen together with a set of control spots to corrected for temperature changes and local 
changes in refractive index. The array is introduced into the array reader where it is illuminated with 
635 nm radiation from an LED in a near-field configuration. Light scattered by the nanoparticles is 
collected by a video camera and averaged to produce a real-time kinetic trace as the patient’s 
serum passes over the array. The array element sensitivity variability is within 15% determined by 
observing the signal change between PBS and 2% glycerol in PBS solutions, with a known RI of 
2.7×10-3. The data are presented in response units (RU) with 1 RU conventionally equivalent to a 
10-6 refractive index change in the bulk analyte (22). Calibration of the kinetic change produces the 
concentration of the target protein – an immuno-kinetic assay. The detection limit may be enhanced 
by a secondary detection antibody, which can further identify the IgG or IgE composition of 
biosensor surface.  
Chemicals 
Bovine serum albumin, BSA (98%), human fibrinogen and FBR (60%) were obtained from 
Sigma-Aldrich. Commercially available purified allergens Fel d1 (cat), Can f1 (dog), Der p1 (dust 
mite), and Ara h1 (peanut), as well as rabbit polyclonal antibodies to Ara h1 were obtained from 
Indoor Biotechnologies UK; goat polyclonal antibodies to rabbit IgG were supplied by AbD Serotec 
UK; goat polyclonal antibodies to human IgE and IgG Fc were obtained from R&D systems. 
Dithiobis-succinimidyl propionate (DTSP, 97%) was from Fluka. The standard buffer used in 
preparation and dilution of the samples was phosphate buffed saline (PBS) with an additional  
0.005% w/w Tween 20 surfactant, supplied by Sigma-Aldrich. A 100 mM aqueous phosphoric acid 
solution was used as regeneration buffer. 
Sensor arrays 
The current study employed 128 rectangular sensor arrays with round spots of ca. 200 m 
diameter and array pitch of 300 m, Fig. 1a. Bio-functionalized sensors were prepared by inkjet 
printing allergens along with BSA and FBR proteins onto DTSP-activated gold (20, 23) arrays spots 
according to the array key shown in Fig. 1a. The printing process delivers a small volume (0.3 nL) 
of the corresponding allergen or protein solution to a single array element, subsequently the array 
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is stored in a 80- humidity chamber for 3-4 hours to complete the immobilisation step. The slides 
are then washed in PBS and stored at 5C until used with an active lifetime of up to three months. 
Clinical samples 
Serum samples were obtained from 10 patients who had been tested positive for peanut 
allergy by specific IgE in the immunology diagnostic laboratory at Derriford Hospital, Plymouth, 
using the Phadia ImmunoCap system. Results were reported in both kUA/l and as a RAST grade 0 
- 6. The study was approved by the National Research Ethics Service Committee South West – 
Cornwall & Plymouth. The patient samples were anonymised and consent was not required. 
Results 
The multi-allergen array performance, Fig. 1, was tested for each of the dog, cat, dustmite 
and peanut allergen proteins in a series of experiments with purified samples of their respective 
anti-allergen antibodies.  Purified allergen-specific human immunoglobulins are not readily available 
commercially for Ara h1 and the sensor response was characterised using standard solutions of 
rabbit anti Ara h 1 polyclonal IgG antibody, a-Ara-IgG. Solutions of known concentrations a-Ara-IgG 
diluted with PBS were injected over the sensor slides for approximately 16 minutes, Fig. 2a. IgG 
concentrations greater than 3 nM show a characteristic kinetic binding response with an association 
rate consistent with an antibody-antigen interaction. A switch to the running PBS buffer leads to 
removal of the adsorbed antibody with a slow dissociation rate. The ratio of the dissociation rate to 
the association defines the affinity of the antibody, typically KD = 10 nM (24). At lower antibody 
concentrations, below the detection limit for the primary binding event, a detection antibody (goat 
anti rabbit IgG) was introduced to bind to the a-Ara-IgG to enhance the signal and identify the 
component binding to the surface. After the primary-secondary detection sequence was completed, 
the sensor was regenerated with 100 mM phosphoric acid solution, shown in Fig. 2a as step (d).  
The observed detection limits for the primary detection event is 300 pM (45 ng ml-1) and 
secondary detection step is 4 pM (6 ng ml-1) ((based on 2 SD noise); a 7-fold enhancement factor. 
The regeneration step allows many measurements to be made using the same array. The 
calibration curves are presented Fig. 2b  and relate explicitly for the concentration determination of 
pure antibodies in PBS dilutions and must be corrected for the effects of the patient sera. The 
presence of other serum proteins in high concentrations extensively affects concentration 
determination and we have derived previously the method to determine quantitatively accurate 
results (19). There are no purified human allergen-specific IgE/IgG for the control assays and an 
approximate quantitative estimate only is possible.  
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The patient sample serum is diluted to 12% in PBS from a patient with known peanut allergy 
RAST grade 5 as determined by the f13 Immunocap assay. The binding specificity was tested on 
the array for Ara h1 is specific to this assay and there is no correlation with binding to epitopes 
presented by Fel d 1, Can f 1 and Der p 1, Fig. 3a. The experimental sequence consists of a 
primary sample injection step, characterised by clearly visible bulk refractive index change 
associated with the bulk refractive index of the serum, followed by a slower surface binding in all 
channels dominated by the response in the Ara h1 assay. Two protein assays for FBR and BSA 
were used as internal control standards for temperature drift, LED intensity changes and as a non-
specific binding reference. After the first buffer wash, an identification assay was performed with 
secondary detection IgG antibodies for the 6 human immunoglobin types: E, G, A, M, and D for 
which only a positive response was observed for IgG.  Finally, the sensor surface was regenerated 
with the phosphoric acid buffer. Further sample injection profiles and kinetic responses may be 
seen in the supplementary material, Fig. S1 and Fig. S2. 
The patient serum set clearly shows specific binding to the Ara h 1 allergen with no 
significant binding to the positive controls. However, there is significant variation in both the total 
sBP and the detected IgE and IgG with varying composition, indicating different immuno-
recognition profiles. Fig. 3b shows the data recorded for a RAST grade 5 sample: a strong primary 
response in specific binding to the peanut allergen channel is followed by slow wash-off when the 
flow was switched from sample to running buffer. Then two detection antibodies were employed to 
identify the surface bound proteins, human anti-IgE and anti-IgG were injected at ca. 25 and 45 
minutes, respectively. The order of injections of the two detection antibodies is important: when 
anti-IgE was injected first, the response is significantly stronger than when it was injected secondly, 
after anti-IgG. The protocol was refined to ensure the IgE detection step is performed first with IgG 
second: the surface concentration estimations were consistent with this detection sequence.  
Determination of the surface concentration of IgG, IgE and sBP requires a calibration step. 
On the assumption that the detection polyclonal antibody has the same epitope affinity as the anti-
rabbit detection antibody, the calibration curve Fig. 2b can be used to derive component 
contributions to the total specific binding mass. The mass balance estimation for the data presented 
in Fig. 3b is : total specific binding protein load, sBP, is equivalent to a solution phase concentration 
of 3.5nM, of which IgE = 0.13nM, IgG = 0.36nM. Only 14% of the total surface concentration may 
be identified, total sBP, indicating that 86% of the total epitope-specific binding is unidentified, sBP 
= 86%. Another example of sBP analysis is presented in the supplementary material, Fig. S3. For 
this RAST grade 6 patient; here the identification  steps show that only 20% of the total protein load 
was identified as IgE or IgG with IgG in a ninefold excess.  
7 
 
The new epitope profile parameters for a patient serum are now sBP, IgE, IgG and sBP 
and these were assessed for the contributions to Ara h 1 for all 10 patient samples, Fig. 4a. The 
left-hand axis shows the observed response, while the right-hand axis is marked with an effective 
total sBP concentration based on assumption that the analyte species has a molecular mass similar 
to the immunoglobulin proteins, 150kDa. The patient cohort consisted of mainly RAST grade 5 and 
6 samples all of whom had demonstrated a clinical allergic response to peanut. Correcting for the 
amplification factor of the detection/identification antibody, Fig. 2b, the identified combined IgE+IgG 
load is significantly lower that the observed total response in sBP, with a mean (IgE+IgG)/sBP = 
0.18 ± 0.10  value (mean ± SD) for the cohort. 
 
Discussion 
We have performed label-free measurements of the total allergen-specific binding to Ara h1 
peanut allergen from a small patient cohort (n=10), Fig. 4a. In each case, the measurements were 
compared with the RAST grade determined by the conventional immunology laboratory methods 
using the Phadia Immuocap specific-IgE test. There is a positive correlation between the 
ImmunoCap and the sensor array Ara h1 total sBP measured values with a correlation coefficient 
R2 = 0.64, Fig. 4b. The f13 epitope presentation is not resolved into the specific Ara h components 
and the specific binding to Ara h1 appears to represent only a small fraction f13 binding, with 
additional binding likely to be attributed to Ara h1 and h3 in the whole peanut extract. Allergen 
surface preparation is important in all instrumental platforms, including the tethering chemistries, to 
ensure there is a sufficiently large surface area of the allergen and that the target eptope is 
presented correctly. In our experiments, the active epitope presentation has been preserved as 
judged by the specific activity of antibodies binding to the surface, (20, 21, 24, 25).   
The ratio of the sensor surface area to the sample size is important: a large surface area will 
allow all serum components sBP, IgG, IgE and sBP to bind to the sensor surface with a 
sufficiently larger number of binding sites to accommodate all proteins. Subsequent detection of IgE 
with an IgE-specific antibody will then give a consistent result for the determination of IgE 
concentration in the patient serum: this is most likely the case for the ImmunoCap platform. 
However, if the surface area binding site capacity is low, the sBP and IgG binding will compete 
kinetically with IgE for the available sites on the sensor surface, Fig. 5, limiting IgE deposition and 
producing a reduced IgE detected level. The array spot surface area is significantly smaller than the 
ImmunoCap platform and, in part, this is compensated for in the choice of a small volume of patient 
serum, 250 µL, so as not to saturate the sensor surface. In this way, we measure the effect of 
kinetic of competitive binding of IgE, IgG and sBP based on their relative concentrations. Epitope 
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presentation and the competitive binding effect will produce different IgE determinations on different 
platforms (10) if the sensor surface.  
The kinetic, however, measurement could be closer to the clinical response where a 
potential allergen protein is covered rapidly by whatever sBP component is present in the serum or 
in the membrane mucosa with only IgE triggering the allergic response. A high concentration of 
competitive component in the patient could provide a potential mechanism for a serum positive, IgE 
patient to not show a clinical response. Desensitisation studies for bee venom have shown patients 
with an increasing exposure to venom have an increasing IgG titre and a consequent decrease in 
IgE titre (26). Further studies however have suggested that simple measurement of serum IgG to 
bee and wasp venom is not sufficient to predict severity of response to a challenge (27). Antibody 
subtype namely IgG4 has also been proposed in the role of blocking antibody (28) where the 
IgG4/IgE ratio for non-allergic bee keepers has been reported as in excess of one thousand.  
In contrast to the IgE- and IgG-specific sensors, the scattering nanoparticle platform can 
measure the total mass of protein binding to a particular allergen and measure the relative binding 
affinities/avidities for the association with the allergen on the surface. The measurement is than a 
sensitivity profile of all of the available epitopes to sBP within the patient’s serum phenotype. 
Subsequent identification and quantification of IgE and IgG (all subtypes) on the surface allows the 
contributions from each of these immunoglobulin to be determined with ratios varying up to 4±2, 
significantly smaller than the protection ratio seen with the non-allergic bee keepers. Two factors 
are however important for protection, the ratio of IgG to IgE and also the absolute concentration of 
IgG: to be protective it must effectively block the available allergen surface area. A protective level 
was not present in the serum of any of the patients tested as all showed clinical symptoms of 
allergy. 
Importantly, and novel to this investigation, using the nanoparticle array sensor surface as 
an epiotope-specific mass sensor has been able to quantify all proteins with specific binding (KD
  ~ 
10 nM<) to the target allergen Ara h1. The determined concentrations of IgE and IgG only account 
for 50% of the total specific binding to the Ara h1 epitope in all patients. Again, the concentration of 
sBP is not protective for the patients at the current levels, but is a new specific binding protein for 
Ara h1 present in the blood of peanut suffers, Fig. 4a. The cumulative effect of the IgG and sBP 
are could therefore be protective as neither are readily displaced from the Ara h1 epitope and 
would block it for IgE binding.  
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Conclusions 
The immuno-kinetic assay approach was used to study patient serum samples on a scattering 
nanoparticle array-format multi-allergen biosensor, focusing on peanut allergy detection. The 
sensors are demonstrably sensitive and selective towards allergen-specific binding producing a 
new epitope profile of the allergy sufferers’ serum. For peanut sufferers specifically, the serum 
epitope-binding profile for Ara h1 was determined, resolving total mass binding to the epitope into 
IgG, IgE and an unknown sBP. The ratio IgG and sBP to IgE and their absolute concentration 
could provide protection for patients, blocking the IgE response kinetically. The ratio IgG/IgE ratio in 
our small patient cohort is 4±2 and does not offer protection for the high RAST grade patients. The 
biosensor platform has potential to identify the presence of new allergen-specific markers against 
specific allergens to understand the clinical presentation of allergy and serum composition and to 
provide a companion diagnostic for new desensitisation immune-therapies.  
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Fig. 1 Experimental platform. a: sensor array bio-functionalization printing mask.  
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Fig. 2 Peanut Ara h1 Calibration. a: kinetic traces with different rabbit a-Ara-IgG antibody 
concentrations in analyte: 5, 1.7, 0.6, 0.2 nM in the order of stronger to weaker responses. Injection 
sequence: a – sample, b – running buffer, c – detection goat anti rabbit IgG (only 0.6 and 0.2 nM 
measurements), d – regeneration. b: standard curves derived from the primary responses, open 
circles, and from enhanced responses after the detection antibody was used, filled circles. The a-
Ara-IgG detection limit in the primary step is 300 pM and after the detection antibody was applied – 
40 pM 
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Fig. 3 Example of the raw sensograms obtained in assay of the peanut allergic, RAST grade 5, 
patient serum. The injection sequence: a – sample consisted of 12% serum diluted in PBS; b – 
PBS buffer, c – anti-IgE (R&D), d – anti-IgE (Bethyl), e – anti-IgGc, f – anti-IgA, g – anti-IgM, h – 
anti-IgD, i – regeneration buffer. The order of sensor channels from top to bottom within sample 
injection: peanut, dust mite, cat, FBR, BSA, dog 
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Fig. 4 Summary of clinical samples tests for peanut allergy. a: response in peanut allergen channel, 
approximate scale equivalent to sBP concentration is linked on the right axis. Samples 1-8 are 
graded as RAST 5 or 6 and are presented with partially resolved IgE (gray) and IgG (black) 
contributions in the total mass response sBP (white). Samples 9 and 10, RAST grade 3, were not 
resolved with detection antibodies. Control samples 11 and 12 are sera graded as RAST 3 and 6 
towards other, non-peanut allergens (cat dander and dust mite), and sample 13 is a control serum 
with no allergy description. b: correlation between observed peanut allergens specific response and 
known allergy grades from clinical laboratory, R2 is 0.64. The ImmunoCap values normally reported 
as kUA/L are converted into nM using IgE molecular weight 180 kDa and 1UA=2.4ng. 
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Fig. 5 Schematic binding of analyte species to the surface functionalized with allergen. In addition 
to specific IgE and IgG there seem to be some extra deposited material X (sBP) either as itself or 
in the form of complexes X-IgE/IgG 
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